Pulmokine
Rensselaer · Founded 2007
About Pulmokine
Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine. The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer.
Company Facts
- Founded: 2007
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.0M
- Funding stage: M&A
- Last round: Debt Financing (Mar 2015)
- Website: http://pulmokine.net
- Phone: +1 518-472-0952
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/pulmokine-3188906 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.